You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, January 2017
|
| DOI | 10.1128/aac.02135-16 |
| Pubmed ID | |
| Authors |
Jennifer R. King, Amit Khatri, Roger Trinh, Rolando M. Viani, Bifeng Ding, Jiuhong Zha, Rajeev Menon |
| Abstract |
The three-direct acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir and dasabuvir ± ribavirin (RBV) is approved for treatment of HCV GT1/HIV-1 co-infection. Results of a pharmacokinetic substudy of 3D and darunavir are presented. HCV/HIV-1 infected subjects were randomized to maintain a darunavir 800 mg once daily (QD) or switch to a darunavir 600 mg twice daily (BID) based antiretroviral regimen. On Study Day 1, subjects received 3D and RBV plus darunavir for 12 weeks. Pharmacokinetic parameters were compared for darunavir with and without 3D. Pharmacokinetic parameters of 3D were compared to historical data. Ten subjects received darunavir QD and 12 subjects received darunavir BID. The central value ratios (90% confidence interval [CI]) for darunavir Cmax, AUC24 and C24 administered QD with 3D vs. alone were 0.92 (0.72, 1.18), 0.83 (0.71, 0.98) and 0.64 (0.44, 0.93), respectively. The ratios (90% CI) for darunavir Cmax, AUC12 and C12 administered BID with 3D were 0.92 (0.76, 1.12), 0.88 (0.73, 1.05) and 0.73 (0.58, 0.92), respectively. Exposures of 3D were similar or slightly lower compared with historical data. All darunavir trough concentrations (Ctrough) associated with an HIV-1 RNA >40 copies/mL were above the darunavir EC50 of 550 ng/mL for resistant virus. The 3D regimen with darunavir QD or BID did not affect darunavir Cmax and AUC, whereas darunavir Ctrough decreased. Changes in pharmacokinetic parameters of 3D were not considered clinically significant. Episodes of intermittent HIV-1 viremia were infrequent and not associated with darunavir Ctrough values below 550 ng/mL. (This study has been registered at ClinicalTrials.gov under identifier NCT01939197.). |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 19% |
| Researcher | 3 | 14% |
| Student > Doctoral Student | 2 | 10% |
| Other | 2 | 10% |
| Student > Bachelor | 2 | 10% |
| Other | 4 | 19% |
| Unknown | 4 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 52% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Business, Management and Accounting | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Psychology | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 5 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2017.
All research outputs
#4,837,286
of 25,377,790 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#4,050
of 15,580 outputs
Outputs of similar age
#89,449
of 422,530 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#144
of 208 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 15,580 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,530 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 208 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.